Challenges of biosimilar medicines in France

Home/Reports | Posted 14/10/2022 post-comment0 Post your comment

After reviewing the key figures [1] and the incentive measures [2] to promote the use of biosimilars in France, Nadia Amer, speaker at BIOS 22 and Health Economics Analyst at Health Product Department of CNAM, presented the challenges that are faced and that leave still much room for improvement for biosimilar uptake in France [3].


These challenges are:
– The high savings potential that can be achieved and the key to a sustainable health budget.
– To that end, they should focus more on information towards patients and prescribers specially in the community-based ones.
– Furthermore, the main focus is to be on the switch between the reference and the biosimilars as new treatments are more and more initiated with the biosimilars.
– Heterogeneous practices between hospital prescribers and non-hospital prescribers: an interesting study on the use of biosimilars in the treatment of rheumatoid arthritis was made and one of the main outcomes was that the share of patients with biosimilar, treated with adalimumab, was very different according to the prescribers. It went from 86% during the hospitalisation, to only 41% when prescribed by hospital for out-patient use and it dropped to 30% when prescribed by community-based practitioners.

This presentation of existing examples and experiences in France and the other ones displayed at BIOS 22, having delivered more value for health thanks to biosimilar medicines, allowed for a debate on key features and enablers to be considered in advancing public health and biosimilar policies.

Related articles
Challenges with implementing benefit-sharing programmes for biologicals in Europe

The US needs to learn from Europe to increasing access to biosimilars


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Recomendaciones para mejorar la regulación de los biosimilares en América Latina

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Recomendaciones para mejorar la regulación de los biosimilares en América Latina

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. Key figures of biosimilar medicines in France []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Oct 14]. Available from:
2. GaBI Online - Generics and Biosimilars Initiative. Incentives promoting use of biosimilar medicines in France []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Oct 14]. Available from:
3. Biosimilar medicines: changing patient care pathways, changing outcomes. Webinar BIOS 22. 28 April 2022, Thursday. Speaker: Nadia Amer, Health Economics Analyst, Health Product Department, Caisse Nationale d’Assurance Maladie (CNAM), France.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010